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parametersAbstract Aim: American phase I studies have reported that the recommended dose of TAS-
102 (trifluridine/tipiracil) was 25 mg/m2 twice a day (b.i.d.), although this schedule did not pro-
vide clinically relevant improvements in a phase II study of advanced gastric cancer (AGC).
However, a pivotal phase III study revealed that TAS-102 at 35 mg/m2 b.i.d. provided a clin-
ically relevant improvement in overall survival (OS) among patients with metastatic colorectal
cancer. Therefore, we re-evaluated the efficacy, safety, and pharmacokinetic parameters of
TAS-102 at 35 mg/m2 b.i.d among Japanese patients with AGC.
Methods: All patients had undergone one or two previous chemotherapy regimens that con-
tained fluoropyrimidine, platinum agents, and taxanes or irinotecan. The primary end-point
target was a disease control rate (DCR) of 50% after 8 weeks of the 35 mg/m2 b.i.d. schedule.
Results: Twenty-nine patients were assessable after completing the 35 mg/m2 b.i.d. schedule.
The investigator-determined DCR was 65.5% (95% confidence interval [CI], 45.7e82.1%)
and the independent central review’s DCR was 51.9% (95% CI, 31.9e71.3%); both results ex-
ceeded the primary end-point target. The median progression-free survival and OS were
2.9 months (95% CI, 1.1e5.3 months) and 8.7 months (95% CI, 5.7e14.9 months), respec-
tively. The grade III/IV adverse events included neutropenia (69.0%), leucopaenia (41.4%),
anaemia (20.7%), and anorexia (10.3%). No AGC-specific toxicities were detected.
Conclusions: The 35 mg/m2 b.i.d. dose of TAS-102 provided positive efficacy and an accept-
able toxicity profile in patients with AGC. A randomised, double-blind, placebo-controlled,
phase III study is ongoing to validate these findings.
Clinical trial registration number: UMIN000007421
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastric cancer is the third leading cause of cancer mor-
tality, with 723,000 estimated deaths each year [1]. Flu-
oropyrimidine and platinum-based chemotherapies, with
or without trastuzumab, are considered the global stan-
dards for first-line chemotherapy in patients with unre-
sectable and recurrent gastric cancer [2,3]. Furthermore,
taxanes, irinotecan, and ramucirumab (a novel vascular
endothelial growth factor receptor-2 antibody) have
recently emerged as standard second-line chemotherapy
options [4e6]. However, the prognosis of patients with
advanced or recurrent gastric cancer remains poor, with
a median overall survival (OS) of 12 months.
TAS-102 (Taiho Pharmaceutical, Tokyo, Japan) is a
novel oral nucleoside antitumour agent that comprised
trifluridine (FTD) and tipiracil hydrochloride (TPI) at a
molar ratio of 1:0.5 [7]. Five independent American phase
I studies have defined the recommended dose schedule for
TAS-102 as a 28-day cycle, with treatment on days 1e5
and 8e12 [8,9], and the maximum tolerated dosage was
defined as 25 mg/m2 twice a day (b.i.d.) in patients with
intensively pre-treated breast cancer. However, an Amer-
ican phase II study of 25 mg/m2 b.i.d. in patients with
advancedgastric cancer (AGC) revealed only 1 case (5.6%)
of stable disease (SD) among 18 patients and that study
was closed after the first stage [10]. A phase I study was
subsequently conducted in Japan, which evaluated a
dosage of 35 mg/m2 b.i.d., using the 28-day cycle from the
American studies. This Japanese study reported grade IV
neutropenia as a dose-limiting toxicity (DLT) in the 35mg/m2 b.i.d. schedule, and a higher dosage (40 mg/m2 b.i.d.)
was considered intolerable [11]. Therefore, a Japanese
randomised phase II study and the international rando-
mised phase III RECOURSE (Randomized, Double-
Blind, Phase 3 Study of TAS-102 plus Best Supportive
Care [BSC] versus Placebo plus BSC in Patients with
Metastatic Colorectal Cancer Refractory to Standard
Chemotherapies) study evaluated the 35 mg/m2 b.i.d.
dosage and reported clinically relevant improvements in
OS and progression-free survival (PFS), compared to the
placebo, among patients with metastatic colorectal cancer
[12,13]. The results of the phase III study supported the
approval of TAS-102 by the US Food and Drug
Administration.
Because two patients with AGC did not exhibit severe
toxicities at the 35 mg/m2 dosage in the Japanese phase I
study [11], we hypothesised that the 35 mg/m2 b.i.d.
dosage of TAS-102 would be feasible in patients with
AGC. Therefore, we planned this open-label, single-
arm, multicenter phase II study to evaluate the efficacy,
safety, and pharmacokinetic (PK) profiles of TAS-102
monotherapy in patients with AGC.2. Methods
2.1. Patient eligibility
This phase II study was conducted at six Japanese
institutions and complied with the Declaration of Hel-
sinki and the Good Clinical Practice guidelines. The
study’s protocol was independently prepared by the
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participating institutions, and is listed in the UMIN
registry (UMIN000007421). Written informed consent
was obtained from all patients.
The key inclusion criteria were age of 20 years;
unresectable or recurrent gastric or oesophagogastric
junction adenocarcinoma; a history of one or two
standard regimens that contained fluoropyrimidine,
platinum derivatives, and taxanes or irinotecan; and
documented progressive disease (PD) based on imaging
data that were obtained during or within 2 months after
the last treatment. The patients also had one or more
measurable lesions, based on the Response Evaluation
Criteria in Solid Tumours (RECIST, version 1.1), an
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 0e2, and adequate organ function.2.2. Study treatment and assessment
A 35 mg/m2 dose of TAS-102 was taken orally twice per
day after meals, during a 28-d schedule with treatment
on days 1e5 and 8e12. We also planned to evaluate the
safety and PK parameters from six patients who were
treated using a 40 mg/m2 b.i.d. dosage in the same cycle.
Treatment continued until tumour progression, unac-
ceptable side-effects, or withdrawal of consent. Anti-
tumour response was evaluated by each investigator at
4 and 8 weeks after treatment initiation, and then every
4e6 weeks, according to the RECIST guidelines. When
treatment was discontinued for any reason, except for
PD, follow-up imaging was performed according to the
planned schedule until disease progression or subse-
quent anticancer treatment.
The primary end-point was the investigator-assessed
disease control rate (DCR) for the 35 mg/m2 b.i.d.
dosage, which was defined as the proportion of patients
with a best overall response of complete response (CR),
partial response (PR), or SD, based on the RECIST
guidelines. DCR was analysed in the per-protocol set
over 8 weeks (PPS8W), which was the subset of patients
who fulfilled the minimum exposure requirement (rela-
tive dose of 0.5) until 8 weeks or who experienced
progression before the minimum exposure requirement
without any major protocol deviation. Tumour response
was confirmed after an independent review by a single
radiologist (HK), who has 9 years of subspecialty
experience in diagnostic oncologic radiology.
The secondary end-points were the objective response
rate, PFS, OS, safety profile, andPKprofile for the 35mg/
m2 b.i.d. dosage. The safety and PK profiles of the 40 mg/
m2 b.i.d. dosage were also assessed. Furthermore, the
dose intensity (DI) and relative DI (RDI) of the 35 and
40 mg/m2 b.i.d. dosages were measured.
Safety analysis was performed in the safety popula-
tion (SP), which comprised patients who received 1
dose of TAS-102. Adverse events (AEs) were assessedaccording to the Common Terminology Criteria for
Adverse Events (CTCAE, version 4.0).
2.3. Statistical considerations
In the 35 mg/m2 b.i.d. group, we considered a DCR of
<30% to be unacceptable. Thus, based on Simon’s
Minimax two-stage design, we required 28 PPS8W pa-
tients to evaluate a null hypothesis (a DCR of 30%)
with a one-sided ɑZ 0.10 and power of 80% to detect a
clinically meaningful DCR (50%). In the first stage, 12
PPS8W patients were to be enrolled, and termination of
the trial would be considered if three patients or less
achieved DCR. The null hypothesis would be rejected if
12 patients experienced disease control. After
completing the first stage, 17 additional patients
(total 29 patients) were recruited for the second stage.
This moderate increase in sample size resulted in
ɑZ 0.12 and 84% power if the same threshold (NZ 12)
for disease control was used. We considered this modi-
fication as acceptable and applied the pre-planned
threshold.
The objective response rate and DCR were calculated
with their exact 95% confidence intervals (CIs). The
KaplaneMeier method was used to analyse PFS and
OS, with estimates for median time-to-event end-points
and the respective 95% CIs. All statistical analyses were
performed using SAS software (release 9.3; SAS Insti-
tute Inc., Cary, NC, USA).2.4. PK analysis
The PK parameters for the 35 and 40 mg/m2 b.i.d.
dosages, and the influence of gastrectomy, were inves-
tigated. Blood samples for the PK analyses were
collected from six patients in the first stage of the 35 mg/
m2 b.i.d. dosage, in the following schedule: before
administration and at 30 min and 1, 2 and 4 h after
administration on days 1 and 12 of the first cycle. In the
40 mg/m2 b.i.d. group, blood samples were collected
from six patients in the following schedule: before
administration and at 15 and 30 min and 1, 2, 4, 6, 8,
and 10 h after administration on days 1 and 12 of the
first cycle. The PK parameters for plasma FTD and TPI
were calculated via non-compartmental methods using
Phoenix WinNonlin software (Pharsight Corpora-
tion, St. Louis, MO, USA). The maximum plasma
concentrations (Cmax) and times to the maximum
plasma concentration (Tmax) were determined using the
highest concentration and the time when it was
observed. The area under the concentrationetime curve
(AUC) was calculated using the linear trapezoidal
method on days 1 and 12. The comparisons of PK pa-
rameters in patients with solid tumours [11] or gastric
cancer with/without gastrectomy were performed using
Student t-test (Cmax and AUC) and the Wilcoxon
signed-rank test (Tmax).
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3.1. Patient disposition
During the first stage, 12 PPS8W patients were enrolled
in the 35 mg/m2 b.i.d. group. Radiological evaluations
revealed that eight patients achieved disease control.
Therefore, we enrolled 17 patients for the second stage.
All 29 enrolled patients were assessable as both SP and
PPS8W. In the 40 mg/m2 b.i.d. group, all six enrolled
patients were assessable as both SP and PPS8W.
3.2. Patient characteristics
In the 35 mg/m2 b.i.d. group (19 men [65.5%]; median
age: 64 years [range: 35e76 years]), all patients had an
ECOG PS of 0e1 (PS 0: 69%; PS 1: 31%) and had
previously been treated using chemotherapy until dis-
ease progression. All patients had received fluoropyr-
imidine and platinum agents, while 18 patients (62.1%)
had received taxanes and 11 patients (37.9%) had
received irinotecan. Sixteen patients had previously un-
dergone gastrectomy (55.2%). The characteristics of the
six patients in the 40 mg/m2 b.i.d. group were similar to
those of the 35 mg/m2 b.i.d. group (Table 1).
3.3. Exposure to chemotherapy
The 35 mg/m2 b.i.d. group underwent a median treat-
ment of three cycles (range: one to seven cycles), sevenTable 1
Patient characteristics.
35 mg/m2
b.i.d.
(NZ 29)
40 mg/m2
b.i.d.
(NZ 6)
N (%) N (%)
Age, years Median (range) 64 (35e76) 58 (34e74)
Sex Male 19 (65.5) 5 (83.3)
Female 10 (34.5) 1 (16.7)
Performance status 0 20 (69.0) 4 (66.7)
1 9 (31.0) 2 (33.3)
Previous gastrectomy Yes 16 (55.2) 2 (33.3)
No 13 (44.8) 4 (66.7)
No. of prior regimens 1 5 (17.2) 1 (16.7)
2 24 (82.8) 5 (83.3)
Reason for
discontinuing
previous treatment
Disease progression 29 (100) 6 (100)
Adverse event 0 (0) 0 (0)
Other 0 (0) 0 (0)
Prior chemotherapeutic
agents
Fluoropyrimidine 29 (100) 6 (100)
Platinum agents 29 (100) 6 (100)
Taxanes 18 (62.1) 3 (50.0)
Irinotecan 11 (37.9) 3 (50.0)
Site of metastasis Lymph nodes 20 (69.0) 4 (66.7)
Liver 9 (31.0) 1 (16.7)
Peritoneum 10 (34.5) 1 (16.7)
Lungs 5 (17.2) 0 (0)
Other 10 (34.5) 2 (33.3)
b.i.d., twice a day.patients (24.1%) required a dose reduction, and nine
patients (31.0%) interrupted their treatment. The RDI of
TAS-102 was maintained in all treatment periods (me-
dian: 80.0%, range: 55.0e100%), and most patients
(82.8%) were treated until disease progression. There
was no marked difference in RDI between the patients
with and without gastrectomy. The RDI of the 40 mg/
m2 b.i.d. group was maintained (median 98.3%, range
83.8e100%), and all six patients were treated until dis-
ease progression (Supplementary Table 1).
3.4. Efficacy
The best overall responses for the 35 mg/m2 b.i.d. group
were evaluated by the investigators and an independent
radiological review (Table 2). The investigators’ assess-
ments of the PPS8W population revealed that 1 patient
achieved PR and 18 patients achieved SD, which cor-
responded to an investigator-assessed DCR of 65.5%
(95% CI, 45.7e82.1%). Nineteen patients achieved dis-
ease control, which exceeded the threshold of 12 pa-
tients, and the lower limit of the 80% CI value (51.9%)
exceeded the predetermined threshold of 30%
(p< 0.0001). Although none of the patients achieved
CR, a decrease in the tumour size was observed in 41.4%
of the patients (Fig. 1). The patients who exhibited a
decrease in tumour size also exhibited a trend towards
prolonged PFS (Fig. 1). In the exploratory analyses of
the 40 mg/m2 b.i.d. group, we observed three cases of
SD and three cases of PD (DCR, 50%).
During the independent central review of the 35 mg/
m2 b.i.d. group, the radiologist concluded that two pa-
tients had no measurable tumour lesions based on the
RECIST guidelines and that three patients who wereTable 2
Efficacy in patients (PPS8W) who were treated using the 35 mg/m2
b.i.d. dose.
By the investigators
(NZ 29)
Central review
(NZ 27)b
CR (N, %) 0 (0) 0 (0)
PR (N, %) 1 (3.4)a 1 (3.7)a
SD (N, %) 18 (62.1) 13 (48.1)
PD (N, %) 10 (34.5) 13 (48.1)
DCR (%); 95% CI 65.5; 45.7e82.1 51.9; 31.9e71.3
RR (%); 95% CI 3.4; 0.1e17.8 3.7; 0.0e19.0
Median PFS
(months); 95% CI
2.9; 1.1e5.3
Median OS
(months); 95% CI
8.7; 5.7e14.9
b.i.d., twice a day; PPS8W, the per-protocol set over 8 weeks popu-
lation; CR, complete response; PR, partial response; SD, stable dis-
ease; PD, progressive disease; DCR, disease control rate; CI,
confidence interval; RR, response rate; PFS, progression-free survival;
OS, overall survival.
a The PR was not confirmed because the patient had to discontinue
the study treatment due to prolonged liver dysfunction.
b The central radiologist judged that two patients had no measurable
tumour lesions.
Fig. 1. Waterfall plot analysis for the 35 mg/m2 twice a day cohort. One patient achieved partial response and the remaining 18 patients
exhibited stable disease. The disease control rate according to the investigators was 65.5% (95% confidence interval, 45.7e82.1%). A
decrease in the tumour size, compared to baseline, was observed in 41.4% of the patients and the patients who exhibited a decrease in
tumour size also exhibited a trend towards longer progression-free survival. CR, complete response; PR, partial response; SD, stable
disease; PD, progressive disease.
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DCR according to the independent central review was
51.9% (95% CI, 31.9e71.3%) (Table 2). However, the
number of patients who achieved disease control
(nZ 14) still exceeded the predetermined threshold of
12 patients.
At the data cut-off point, all patients in the 35 mg/m2
b.i.d. group had experienced disease progression and 20
patients had died. The median investigator-assessed
PFS was 2.9 months (95% CI, 1.1e5.3 months)
(Fig. 2, Table 2), and 36.4% (95% CI, 19.4e53.7%) of
the patients were free from progression at 4 months.
After a median follow-up of 17.1 months, the median
OS was 8.7 months (95% CI, 5.7e14.9 months) (Fig. 2,
Table 2).
3.5. Safety
The common grade III/IV AEs in the 35 mg/m2 b.i.d.
group were neutropenia (69.0%), leucopaenia (41.4%),
anaemia (20.7%), and anorexia (10.3%) (Table 3).
Serious AEs were reported for eight patients, although
seven of these eight patients did not exhibit a
confirmed causal relationship between TAS-102 treat-
ment and the AEs. One case of febrile neutropenia
occurred, although no treatment-related deaths were
reported. Most patients (96.5%) underwent treatment
as outpatients. Only one patient experienced a >10%
reduction in body weight during the treatment.Although grade III/IV neutropenia (83.3%) and leu-
copaenia (66.7%) were slightly more frequent in the
40 mg/m2 b.i.d. group, we did not observe any signif-
icant differences in the toxicity profiles for the 35 and
40 mg/m2 b.i.d. dosages (Table 3).
3.6. PK analysis
When we compared the PK parameters for FTD and
TPI between the 35 and 40 mg/m2 b.i.d. dosages, the
average Cmax and AUC values for FTD and TPI
exhibited dose-dependent increases (Table 4). There
were no significant differences in the Cmax, AUC, and
Tmax values for FTD and TPI at the 35 mg/m
2 b.i.d.
dosage when we compared the patients with and without
gastrectomy (Supplementary Table 2).
4. Discussion
The 35 mg/m2 b.i.d. dosage schedule for TAS-102
monotherapy provided an investigator-assessed DCR
of 65.5%. Furthermore, the independent review’s DCR
was 51.9%. Despite this adjustment, the number of pa-
tients who achieved disease control exceeded the
threshold of 12 patients in both analyses. Moreover,
41.4% of the patients experienced a decrease in tumour
size, with a median PFS of 2.9 months and a median OS
of 8.7 months. Therefore, we conclude that the 35 mg/
m2 b.i.d. dosage of TAS-102 provided clinically relevant
Fig. 2. KaplaneMeier plots of PFS and OS in the 35 mg/m2 twice
a day cohort. At the data cut-off point (15th January 2014), all
patients had experienced disease progression. (A) The
investigator-determined median PFS was 2.9 months (95% confi-
dence interval [CI], 1.1e5.3) and 36.4% (19.4e53.7) of the patients
were progression free at 4 months. (B) At the data cut-off point, 20
patients had died. Based on a median follow-up time of 17.1
months, the median OS was 8.7 months (95% CI, 5.7e14.9). OS,
overall survival; PFS, progression-free survival; PPS8W, the per-
protocol set over 8 weeks population.
Table 3
Major adverse events.
35 mg/m2 b.i.d. (NZ 29) 40 mg/m2 b.i.d. (NZ 6)
Any grade N (%) Grade III/IV N (%) Any grade N (%) Grade III/IV N (%)
Haematological
Neutropenia 25 (86.2) 20 (69.0) 6 (100) 5 (83.3)
Febrile neutropenia 1 (3.4) 1 (3.4) 0 (0) 0 (0)
Leucopaenia 26 (89.7) 12 (41.4) 6 (100) 4 (66.7)
Anaemia 25 (86.2) 6 (20.7) 5 (83.3) 1 (16.7)
Non-haematological
Anorexia 24 (82.8) 3 (10.3) 4 (66.7) 1 (16.7)
Nausea 19 (65.5) 1 (3.4) 4 (66.7) 1 (16.7)
Vomiting 8 (27.6) 1 (3.4) 2 (33.3) 1 (16.7)
Diarrhoea 10 (34.5) 0 (0) 2 (33.3) 0 (0)
Abdominal pain 5 (17.2) 0 (0) 0 (0) 0 (0)
Constipation 5 (17.2) 0 (0) 2 (33.3) 0 (0)
b.i.d., twice a day.
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colorectal cancer) in patients with AGC who had been
treated using fluoropyrimidine, platinum, and taxanes
or irinotecan.A recent international phase III study reported that
ramucirumab provided significant improvements in PFS
and OS, compared to a placebo, in patients with AGC
who failed first-line platinum- or fluoropyrimidine-
containing chemotherapy (median PFS: 2.1 months;
median OS: 5.2 months) [6]. Interestingly, the present
single-arm phase II study of TAS-102 monotherapy
revealed favourable median PFS and OS values in pa-
tients with AGC, compared to those in the ramucirumab
study. Furthermore, the present study examined the
toxicity profile of TAS-102, which was comparable to
those from phase II and phase III studies of patients
with colorectal cancer. Moreover, we did not observe
any disease-specific toxicities or complications in the
present study, and the PK analyses revealed FTD con-
centrations that were similar to those in patients with
solid tumours from the Japanese phase I trial [11].
Finally, we did not observe any significant differences in
the PK parameters when we compared patients with and
without gastrectomy.
In the Japanese phase I trial of TAS-102, the 35 mg/m2
b.i.d. dosage was recommended by the Data and Safety
Monitoring Board because they expected higher fre-
quencies of grade IV neutropenia and DLTs at the higher
dose, despite the maximum tolerated dose not being
reached [11]. In the present trial, we evaluated the toxicity
and PK profiles of the 40 mg/m2 b.i.d. dosage and
observed a dose-dependent increase in the concentration
of FTD (versus that from the 35 mg/m2 b.i.d. dosage). In
contrast, there were no significant differences in these two
dosages’ toxicity profiles, although grade III/IV neu-
tropenia and leucopaenia were slightly more frequent at
the 40 mg/m2 b.i.d. dosage. Nevertheless, the DCR at the
40 mg/m2 b.i.d. dosage was 50.0% (SD: three patients;
PD: three patients), and no patients achieved PR.
Therefore, these results suggest that the 35 mg/m2 b.i.d.dosage of TAS-102 provides positive clinical, toxicity,
and PK-related outcomes in patients with AGC.
In conclusion, the 35 mg/m2 b.i.d. dosage of TAS-
102 monotherapy may be a useful treatment option
Table 4
Pharmacokinetic parameters of trifluridine and tipiracil hydrochloride in patients with gastric cancer.
Solid tumoura Gastric cancer
35 mg/m2 b.i.d. (NZ 6) 35 mg/m2 b.i.d. (NZ 6) 40 mg/m2 b.i.d. (NZ 6)
Day 1 Day 12 Day 1 Day 12 Day 1 Day 12
FTD
Cmax (ng/ml) 3338 767 4752 1697 4540 1340 6560 1200 3990 1340 5870 1780
Tmax (h) 1.3 0.5 1.9 1.6 1.0 0.5 1.5 0.5 2.0 1.1 2.2 1.0
AUC0e10 (ng$h/ml) 8678  1786b 20,950 2237 7670  1580c 18,100  5770c 12,000 3900 31,300 10,300
AUCinf (ng$h/ml) 8672 1710 e e e 12,300 4200 35,100 12,100
t1/2 (h) 1.41 0.38 1.97 0.51 e e 1.58 0.39 2.50 0.49
TPI
Cmax (ng/ml) 76.6 32.1 70.0 43.4 85.6 29.7 100 41 89.5 48.2 98.1 36.9
Tmax (h) 2.3 0.8 2.3 0.8 2.0 0.0 1.8 0.4 3.3 1.0 3.3 1.6
AUC0e10 (ng$h/ml) 281  99b 317 182 231  79c 303  149c 422 170 466 159
AUCinf (ng$h/ml) 302 96 e e e 446 178 521 185
t1/2 (h) 1.67 0.22 2.37 0.93 e e 1.67 0.11 2.02 0.40
b.i.d., twice a day; FTD, trifluridine; Cmax, mean maximum plasma concentration; Tmax, time to reach Cmax; AUC, area under the curve; t1/2,
elimination half-life; TPI, tipiracil hydrochloride.
a Reported in reference Doi et al. [11].
b nZ 5.
c AUC0e4.
H. Bando et al. / European Journal of Cancer 62 (2016) 46e5352for patients with AGC. Based on the results of the
present study, a randomised, double-blind, placebo-
controlled, phase III study is ongoing
(NCT02500043).Conflict of interest statement
All authors have provided complete disclosures
regarding their potential conflicts of interest. In partic-
ular, Kei Muro, Tomohiro Nishina, and Atsushi Ohtsu
have received honoraria and Akihiro Sato and Shunji
Takahashi have received research funding from the
Taiho Pharmaceutical Company.Acknowledgements
This study was supported by a grant from the
Renovation Project of Early and Exploratory Clinical
Trial Center, National Cancer Center Research and
Development Fund (24-A-1). The study design, data
collection, data analysis, and data interpretation were
supported by the Early Oncology Research and Clinical
Trial Center, National Cancer Center, Japan (NCC-
EPOC). Taiho Pharmaceutical Company provided the
study drugs and performed the PK analyses. We thank
the patients, their families, and all the investigators who
participated in this study.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.ejca.2016.04.009.References
[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C,
Rebelo M, et al. Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN. Int J
Cancer 2012;2014.
[2] Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J,
et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: a
randomised phase III noninferiority trial. Ann Oncol 2009;
20(4):666e73.
[3] Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,
Sawaki A, et al. Trastuzumab in combination with chemotherapy
versus chemotherapy alone for treatment of HER2-positive
advanced gastric or gastro-oesophageal junction cancer (ToGA):
a phase 3, open-label, randomised controlled trial. Lancet 2010;
376(9742):687e97.
[4] Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC,
et al. Salvage chemotherapy for pretreated gastric cancer: a
randomized phase iii trial comparing chemotherapy plus best
supportive care with best supportive care alone. J Clin Oncol
2012.
[5] Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY,
Wadsley J, et al. Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): an
open-label, phase 3 randomised controlled trial. Lancet Oncol
2014;15(1):78e86.
[6] Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R,
Goswami C, et al. Ramucirumab monotherapy for previously
treated advanced gastric or gastro-oesophageal junction adeno-
carcinoma (REGARD): an international, randomised, multi-
centre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):
31e9.
[7] Tanaka N, Oguchi K, Fujita R. Trifluorothymidine incorporation
into DNA strongly enforces the potential of TAS-102 and leads to
remarkably prolonged survival of cancer patients. Cancer Res
2012;15:1783. American Association for Cancer Research; Chi-
cago, IL, USA.
[8] Overman MJ, Kopetz S, Varadhachary G, Fukushima M,
Kuwata K, Mita A, et al. Phase I clinical study of three times a
H. Bando et al. / European Journal of Cancer 62 (2016) 46e53 53day oral administration of TAS-102 in patients with solid tumors.
Cancer Invest 2008;26(8):794e9.
[9] Overman MJ, Varadhachary G, Kopetz S, Thomas MB,
Fukushima M, Kuwata K, et al. Phase 1 study of TAS-102
administered once daily on a 5-day-per-week schedule in pa-
tients with solid tumors. Invest New Drugs 2008;26(5):445e54.
[10] Peters GJ. Therapeutic potential of TAS-102 in the treatment of
gastrointestinal malignancies. Ther Adv Med Oncol 2015;7(6):
340e56.
[11] Doi T, Ohtsu A, Yoshino T, Boku N, Onozawa Y,
Fukutomi A, et al. Phase I study of TAS-102 treatment inJapanese patients with advanced solid tumours. Br J Cancer
2012;107(3):429e34.
[12] Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-
Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102
for refractory metastatic colorectal cancer. N Engl J Med 2015;
372(20):1909e19.
[13] Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y,
Baba H, et al. TAS-102 monotherapy for pretreated metastatic
colorectal cancer: a double-blind, randomised, placebo-controlled
phase 2 trial. Lancet Oncol 2012;13(10):993e1001.
